|
EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
{contributors}
|
To view the clinical trial data of the following topics click
here (pdf format)
Contributors were selected by Jean A. Maroun,
MD, FRCPC, FRCP; Joseph Ragaz, MD, FRCPC; and Amil Shah, MD, FRCPC
Colorectal
cancer
Lyly H. Lê, MDCM, FRCPC
RANDOMIZED PHASE III STUDY OF CAPECITABINE,
OXALIPLATIN, AND BEVACIZUMAB WITH OR WITHOUT CETUXIMAB IN ADVANCED
COLORECTAL CANCER (ACC), THE CAIRO2 STUDY OF THE DUTCH COLORECTAL
CANCER GROUP (DCCG). ASCO 2008, ABSTRACT LBA4011.
Investigators: C.J. Punt et
al.
Pancreatic
cancer
Howard J. Lim,
MD, PhD, FRCPC and Hagen Kennecke, MD, MPH, FRCPC
CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER
PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS
OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER (PC). ASCO
2008, ABSTRACT LBA4504.
Investigators: P. Neuhaus et al.
Early-stage
breast cancer
Caroline Lohrisch,
MD, FRCPC
STANDARD CHEMOTHERAPY (CMF OR AC) VERSUS CAPECITABINE IN EARLY-STAGE
BREAST CANCER (BC) PATIENTS AGED 65 AND OLDER: RESULTS OF CALGB/CTSU
49907. ASO 2008, ABSTRACT 507.
Investigators: H.B. Muss et al.
INTERIM RESULTS OF INTERGROUP EC-DOC TRIAL:
A RANDOMIZED MULTICENTER PHASE III TRIAL COMPARING ADJUVANT CEF/CMF
TO EC- DOCETAXEL IN PATIENTS WITH 1-3 POSITIVE LYMPH NODES. ASCO
2008, ABSTRACT 515.
Investigators: U. Nitz et al.
RANDOMIZED PHASE III TRIAL COMPARING THE SEQUENTIAL
ADMINISTRATION OF DOCETAXEL FOLLOWED BY EPIRUBICIN PLUS CYCLOPHOSPHAMIDE
VERSUS FE75C AS ADJUVANT CHEMOTHERAPY IN AXILLARY LYMPH NODE-POSITIVE
BREAST CANCER. ASCO 2008, ABSTRACT 521.
Investigators: D. Mavroudis et al.
Premenopausal
breast cancer
Debjani Grenier,
MD, FRCPC
ADJUVANT OVARIAN SUPPRESSION COMBINED WITH TAMOXIFEN OR ANASTROZOLE,
ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID, IN PREMENOPAUSAL WOMEN
WITH HORMONE-RESPONSIVE, STAGE I AND II BREAST CANCER: FIRST EFFICACY
RESULTS FROM ABCSG-12. ASCO 2008, ABSTRACT LBA4.
Investigators: M. Gnant et al.
Vitamin
D and breast cancer
Joseph Ragaz,
MD, FRCPC
FREQUENCY OF VITAMIN D (VIT D) DEFICIENCY AT BREAST CANCER (BC)
DIAGNOSIS AND ASSOCIATION WITH RISK OF DISTANT RECURRENCE AND DEATH
IN A PROSPECTIVE COHORT STUDY OF T1-3, N0-1, M0 BC. ASCO 2008, ABSTRACT
511.
Investigators: P.J. Goodwin et al.
To view the clinical trial data click
here (pdf format)
|
